News for OKYO Pharma Limited (OKYO.L)

LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ( OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing ur

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as meas

**media[651787]**

OKYO Pharma's CEO to present at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston on May 22, 2025. The presentation will focus on urcosimod, a d

LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ( OKYO), a clinical-stage biopharmaceutical company developing innovative therapies

LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ( OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urc

Urcosimod phase 2 trial treating Neuropathic Corneal Pain (”œNCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-wee

LONDON and NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ( OKYO), a clinical-stage biopharmaceutical company developing innovative therapie

**media[538641]**

LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ( OKYO), a clinical-stage biopharmaceutical company developing innovative therapies

**media[476539]**

**media[451174]**

**media[438240]**

OKYO begins patient enrollment for Phase 2 NCP trial

France-based semiconductor business Sequans Communications S.A. (SQNS) is up over 146 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

OKYO Pharma secures key European patent for eye treatment

Loading... Loading... Shares of Conagra Brands, Inc. CAG fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales res...

OKYO Pharma maintains stock target, Buy rating amid positive trial data

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.